Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Tanner J. Schumacher ; Ananth V. Iyer ; Jon Rumbley , et al. bioRxiv,2024:2024.05.02.592272. DOI: 10.1101/2024.05.02.592272
More
Abstract: Cancer cells alter their metabolic phenotypes with nutritional change. Single agent approaches targeting mitochondrial metabolism in cancer have failed due to either dose limiting off target toxicities, or lack of efficacy in vivo. To mitigate these clinical challenges, we investigated the potential utility of repurposing FDA approved mitochondrial targeting anthelmintic agents, niclosamide and pyrvinium pamoate, to be combined with GLUT1 inhibitor BAY-876 to enhance the inhibitory capacity of the major metabolic phenotypes exhibited by tumors. To test this, we used breast cancer cell lines MDA-MB-231 and 4T1 which exhibit differing basal metabolic rates of glycolysis and mitochondrial respiration, respectively. Here, we found that specific responses to mitochondrial and glycolysis targeting agents elicit responses that correlate with tested cell lines basal metabolic rates and fuel preference, highlighting the potential to cater metabolism targeting treatment regimens based on specific tumor nutrient handling. Inhibition of GLUT1 with BAY-876 potently inhibited glycolysis in both MDA-MB-231 and 4T1 cells, and niclosamide and pyrvinium pamoate perturbed mitochondrial respiration that resulted in potent compensatory glycolysis in the cell lines tested. In this regard, combination of BAY-876 with both mitochondrial targeting agents resulted in inhibition of compensatory glycolysis and subsequent metabolic crisis. These studies warrant further investigation into targeting tumor metabolism as a combination treatment regimen that can be tailored by basal and compensatory metabolic phenotypes.
CAS No. : | 328-74-5 | MDL No. : | MFCD00000394 |
Formula : | C8H5F6N | Boiling Point : | - |
Linear Structure Formula : | C6H3(CF3)2(NH2) | InChI Key : | CDIDGWDGQGVCIB-UHFFFAOYSA-N |
M.W : | 229.12 | Pubchem ID : | 9480 |
Synonyms : |
|
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
[ 96100-12-8 ]
3-Amino-5-methylbenzotrifluoride
Similarity: 1.00
[ 368-53-6 ]
5-(Trifluoromethyl)benzene-1,3-diamine
Similarity: 0.98
[ 368-71-8 ]
4-(Trifluoromethyl)benzene-1,2-diamine
Similarity: 0.95
[ 243128-44-1 ]
2-Methyl-3,5-bis(trifluoromethyl)aniline
Similarity: 0.93
[ 96100-12-8 ]
3-Amino-5-methylbenzotrifluoride
Similarity: 1.00
[ 368-53-6 ]
5-(Trifluoromethyl)benzene-1,3-diamine
Similarity: 0.98
[ 368-71-8 ]
4-(Trifluoromethyl)benzene-1,2-diamine
Similarity: 0.95
[ 243128-44-1 ]
2-Methyl-3,5-bis(trifluoromethyl)aniline
Similarity: 0.93
[ 96100-12-8 ]
3-Amino-5-methylbenzotrifluoride
Similarity: 1.00
[ 368-53-6 ]
5-(Trifluoromethyl)benzene-1,3-diamine
Similarity: 0.98
[ 368-71-8 ]
4-(Trifluoromethyl)benzene-1,2-diamine
Similarity: 0.95
[ 243128-44-1 ]
2-Methyl-3,5-bis(trifluoromethyl)aniline
Similarity: 0.93
[ 96100-12-8 ]
3-Amino-5-methylbenzotrifluoride
Similarity: 1.00
[ 368-53-6 ]
5-(Trifluoromethyl)benzene-1,3-diamine
Similarity: 0.98
[ 368-71-8 ]
4-(Trifluoromethyl)benzene-1,2-diamine
Similarity: 0.95
[ 243128-44-1 ]
2-Methyl-3,5-bis(trifluoromethyl)aniline
Similarity: 0.93